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Riboswitches in the 50-untranslated regions of mRNAs
cotranscriptionally couple ligand binding and gene
regulation. In this issue of Chemistry & Biology,
Lemay et al. [1] describe folding of a key tertiary inter-
action in the adenine riboswitch and its mechanistic
consequences.
Folding from a nascent chain into a biologically func-
tional entity is an essential stage in the life of every mac-
romolecule. For most proteins and RNAs, a crucial
feature of folding is that all pathways lead to a single
productive conformation, limiting misfolded or inactive
species. Only after acquiring native structure do these
molecules begin to respond to their cellular environ-
ment, making ‘‘decisions’’ such as whether a repressor
will bind to a DNA operator or a kinase will phosphory-
late its target protein. Riboswitches, a recently discov-
ered type of genetic regulatory element found in the 50-
untranslated regions (50-UTR) of a number of bacterial
mRNAs (reviewed in [2]), differ from this theme in that
the folding process leads to one of two distinct biologi-
cal outcomes: gene expression or repression. These
regulatory sequences function in the absence of associ-
ated proteins and in response to cellular levels of partic-
ular small-molecule metabolites. Complicating this
process is the fact that coupled folding and ‘‘decision-
making’’ occurs cotranscriptionally such that the final
outcome is set before the polymerase escapes the 50-
UTR, a critically important feature for riboswitches that
regulate at the transcriptional level. In the current issue
of Chemistry & Biology, Lafontaine and colleagues pro-
vide new insights into the first stage of this process
through their investigation of the coupling between fold-
ing of the adenine riboswitch ligand recognition domain
and its ability to productively bind adenine [1].
Riboswitches are composed of two overlapping do-
mains: a 50 aptamer domain responsible for binding a
specific metabolite and a downstream expression plat-
form that controls gene expression. Switching between
expression and repression is accomplished by the ex-
pression platform, which adopts one of two mutually
exclusive secondary structures (in the case of transcrip-
tional regulation, either an antiterminator or a terminator
element), depending upon whether the aptamer domain
has bound the appropriate ligand. The aptamer domain
of the adenine riboswitch, as well as the structurally re-
lated guanine riboswitch, comprises a compact three-
way junction structure (Figure 1A) [3–6]. Loops capping
the P2 and P3 helices, which contain a number of highly
phylogenetically conserved nucleotides, interact though
two base quadruples and a noncanonical base pair (Fig-
ure 1A, cyan). The ligand binding pocket is formed by
a three-way junction in which the purine nucleobase is
the keystone for another set of tertiary interactions
between the joining regions (Figure 1A, J1/2, J2/3, andJ3/1). Purine specificity is dictated by a single pyrimidine
residue (denoted by an asterisk in Figure 1) that interacts
with the ligand through Watson-Crick base pairing to
yield a w20,000-fold discrimination between guanine
and adenine [3, 4].
A key feature of the adenine riboswitch is a tertiary in-
teraction between the terminal loops (L2 and L3) whose
proper formation is essential for ligand binding [3]. As a
first step toward understanding how this element of ar-
chitecture serves to establish the global fold of the ap-
tamer domain, Lafontaine and coworkers [1] extensively
mutagenized residues in the loops to determine their
relative importance for riboswitch function. Despite the
universal conservation of many of these nucleotides,
most can be altered with only a small impact upon ligand
binding. The structurally important core of this interac-
tion appears to be two G-C Watson-Crick pairs (G37-
C61 and G38-C60 in Figure 1A) that form part of each
quartet. Even more surprising from a structural perspec-
tive is that the sequence of the two loops can be swap-
ped without loss of affinity for adenine. Together, these
results indicate that the loop-loop interaction is plastic
and able to compensate for many mutations, despite
the fact that over half these nucleotides are phylogenet-
ically invariant.
One of the primary questions about the folding of the
adenine riboswitch is how does the acquisition of ter-
tiary architecture facilitate ligand binding? Single-mole-
cule FRET studies provide a unique perspective into this
process. Lemay et al. report results obtained by labeling
the loops with a FRET donor-acceptor pair (stars in Fig-
ure 1) [1]. Under low magnesium ion conditions (<50 mM)
the RNA experiences three folding states, described
by the authors of the current study as ‘‘U,’’ ‘‘I,’’ and ‘‘F’’
[1]. The unfolded state (U) represents the RNA with all
of its secondary structural elements formed (P1, P2,
and P3), but with no tertiary structure. In this state, the
three helices are likely to be splayed apart, similar to
what is observed in other three-way junctions (Figure 1B)
[7–9]. The folded state (F), conversely, represents a glob-
ally organized state in which the loop-loop interaction
brings P2 and P3 together, priming the RNA for ligand
recognition. However, in-line probing [4], NMR [6], and
mechanistic studies [10] have indicated that the three-
way junction remains locally disordered to allow for
ligand binding.
Surprisingly, there is an intermediate folding state (‘‘I’’)
that is observed. While the authors do not speculate as
to the nature of this conformation, when considered in
the light of other studies, a reasonable model for this
process can be proposed. In the absence of ligand,
the three-way junction is not completely disordered;
rather, one strand of the three-way junction, J3/1, is pre-
organized to present a pyrimidine residue that forms the
Watson-Crick pair with exogenous adenine or guanine
[10]. Only upon productive pairing between the ligand
and this pyrimidine (U65 of the riboswitch studied by
the Lafontaine group) do J1/2 and J2/3 close around
the ligand, forming the extensive set of interactions
Chemistry & Biology
806Figure 1. Structure of the Adenine Riboswitch and a Proposed Mechanism for Folding and Ligand Binding
(A) Secondary (left) and three-dimensional (right) structures of the add adenine riboswitch from V. vulnificus (PDB ID 1Y26). The cyan region rep-
resents the two loops (L2 and L3) that were studied in the work of Lemay et al. [1]. The three-way junction (green) contains the adenine (magenta)
binding pocket. The red and yellow stars denote the two uridines that were labeled with FRET probes.
(B) A proposed mechanism by which folding and ligand binding are coupled in the adenine riboswitch. The U, I, and F/F* states were observed
directly in single-molecule FRET studies. The elements of structure highlighted by orange circles are those that are organized in each step of the
folding/binding mechanism. If the aptamer domain does not bind ligand, the RNA takes a second pathway leading to the Fz state containing an
antiterminator stem loop (AT).that make the nucleobase almost completely solvent in-
accessible [3, 6]. One possibility is that the ‘‘I’’ state rep-
resents the coaxial stacking of the P1 and P3 helices
along with the bases in J3/1 in the absence of the L2-
L3 interaction (Figure 1B). In this state, L2 and L3 would
be brought closer together, leading to the detected in-
termediate FRET signal. Formation of the loop-loop in-
teraction would stabilize the P1-J3/1-P3 stacking,
thereby promoting ligand binding.During transcription, the aptamer domain is first
synthesized by RNA polymerase and folds indepen-
dently of the expression platform. A stretch of uridines
following the aptamer domain causes the polymerase
to stall temporarily, enabling temporal separation of
the two folding events [11, 12]. Transcriptional pausing
is important for the riboswitch’s ability to bind metabo-
lite; an RNA that does not experience this temporal de-
coupling of the two folding events binds adenine very
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807poorly, if at all [3, 6]. In other cases where ligand binding
is kinetically slow compared to the rate of transcription
(e.g., for the FMN [12] and purine [11] riboswitches),
pausing allows the aptamer domain sufficient time to
bind ligand if the metabolite’s intracellular concentration
is sufficiently high. This binding interaction allows the
RNA to proceed from the F to F* state (Figure 1B). For
the pbuE adenine riboswitch [5], acquisition of the F*
state determines that transcription will be aborted and
thus turns off gene expression.
In the absence of ligand, the 30 side of the P1 helix dis-
sociates from the aptamer domain and is used to form
a stem-loop structure in the expression platform that
dictates the second genetic outcome, upregulation of
transcription (Figure 1B). A second pause site, usually
found in the middle of the expression platform, enables
riboswitches to perform the intrinsically slow second-
ary structural rearrangement (F/ Fz in Figure 1B) that
leads to active transcription of the downstream coding
sequence [12].
Previous studies have noted the necessity for the
loop-loop interaction in ligand recognition, but they were
unable to provide a plausible connecting mechanism.
This coupling is an important issue, as three-way junc-
tions are a ubiquitous structural motif for higher-order
organization of RNA, involved in forming protein binding
and catalytic active sites [13]. Characterization of the
natural (‘‘fast’’) hammerhead ribozyme revealed that a
loop-loop interaction facilitates organization of the cat-
alytic site located in a three-way junction, allowing it
to cleave at greatly accelerated rates in physiologically
relevant magnesium concentrations [14, 15]. Strikingly,
this RNA has strong architectural similarities to the
adenine riboswitch, illustrating that organization of
functional RNA junctions is often facilitated by other
elements of tertiary structure [16]. These recent
studies underscore that we are still just beginning to
understand how the ability of RNA to fold into intricateChemistry & Biology 13, August 2006 ª2006 Elsevier Ltd All rights reserved
Discovering New
MAP Kinase Inhibitors
The current study by Kim et al. [1] (in this issue of
Chemistry & Biology) uses a genetic approach with
the yeast Schizosaccharomyces pombe to identify a
highly specific inhibitor of Spc1 MAP kinase that com-
petes with protein substrates for Spc1 interactions,
but not with ATP binding.
Mitogen activated protein (MAP) kinases are key signal-
ing proteins that mediate cellular responses to extracel-
lular signals. Overactivation of the MAP kinase signalingthree-dimensional structures allows them to execute
their diverse cellular functions.
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pathways, primarily through genetic mutations of up-
stream regulatory proteins, is thought to play a prominent
role in inflammatory diseases and tumor cell prolifera-
tion [2]. Thus, there is wide interest in the development
of specific and effective MAP kinase inhibitors. In this is-
sue of Chemistry & Biology [1], Kim et al. describe the
identification of a highly specific, small molecular weight
isoquinolinium compound that appears to inhibit only
a specific MAP kinase isoform found in the yeastSchizo-
saccharomyces pombe (S. pombe) but has little effect
on the activity of other yeast MAP kinases, MAP kinase
activators, or homologous MAP kinases from mamma-
lian species. These findings may help set the stage for
the development of highly specific and hopefully more
clinically effective MAP kinase inhibitors.
